Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price target at $83.00.
Sam Slutsky has given his Buy rating due to a combination of factors, primarily centered around the promising data from CG Oncology’s Phase 3 BOND-003 study. The study, which evaluates their lead asset, cretostimogene, shows a high anytime complete response rate of 75.5% among patients with high-risk BCG-unresponsive NMIBC, which is an improvement from previous data. Additionally, the 12-month and 24-month complete response rates remain robust, indicating sustained efficacy over time.
Moreover, cretostimogene continues to demonstrate a favorable safety profile, with no Grade ≥3 treatment-related adverse events reported and a quick resolution time for any adverse events. The absence of systemic shedding in patients further supports the safety of the treatment. These positive clinical outcomes, combined with the company’s strategic management and financial metrics, underpin Slutsky’s confidence in recommending a Buy rating for CG Oncology’s stock.
According to TipRanks, Slutsky is an analyst with an average return of -6.5% and a 31.95% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, Astria Therapeutics, and Spyre Therapeutics.